J&J to pay $181 million for Risperdal settlement

Share this article:
J&J to pay $181 million for Risperdal settlement
J&J to pay $181 million for Risperdal settlement
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.
 
The payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients with Alzheimer's and dementia, Reuters reported. The drug, which is intended to treat schizophrenia, is not approved for these conditions.
 
Although it is legal for physicians to prescribe drugs such as Risperdal for unapproved indications, manufacturers are forbidden from promoting the drug to providers for such uses. Risperdal often is used in nursing homes to sedate agitated memory care residents. Regulators and provider groups have been working to reduce this practice.

J & J has been involved in several multimillion-dollar settlements with regard to Risperdal in recent months. In March, federal prosecutors rejected a $1 billion settlement with J & J over Risperdal.
Share this article:

More in News

Involving nursing assistants with decisions may result in higher quality, study finds

Empowering nursing assistants and family members of nursing home residents in decision-making results improved service, a new study finds.

Also in the news for July 28, 2014 . . .

Nursing home aide accused of choking a resident....Monitoring pulse after stroke may prevent another stroke...Slow walking speed may predict dementia

Site-neutral payments likely to move forward, experts believe

Site-neutral payments likely to move forward, experts believe

As the Centers for Medicare & Medicaid Services and the Medicare Payment Advisory Commission evaluate site-neutral payments, a new brief from Health Affairs and the Robert Wood Johnson Foundation explores ...